AlzeCure publishes new data on NeuroRestore and ACD856 from Alzheimer’s conference

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s presentations at the Alzheimer’s conference 2nd Swedish Meeting for Alzheimer Researchregarding the research platform NeuroRestore and its primary drug candidate ACD856, are now available in their entirety on the company’s website.

The presentations, worthy Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk Receptorsand A Positive Modulator of Neurotrophin Receptors Improve Cognition and Mitochondrial Functionwere given by Kristin Önnestam, Clinical Project leader, and Cristina Parrado-Fernández, Senior Scientist. The results presented include new data from the clinical phase I Single Ascending Dose study which shows that ACD856 shows a good safety and tolerability profile in humans as well as suitable pharmacokinetic properties, which supports the further clinical development of the substance. ACD856, which is primarily developed for the treatment of Alzheimer’s disease, is being tested in an ongoing clinical phase I multiple Ascending Dose study that is expected to be read out in the summer of 2022.

Results from the conference also exhibited new preclinical data showing a dose-dependent positive effect of the NeuroRestore substance AC-0027136 on mitochondrial function, which is particularly interesting as impaired mitochondrial function is common in disorders such as Alzheimer’s disease. The results also showed that AC-0027136, like ACD856, had a positive effect on long-term memory in aged animals.

“The results we presented show that the NeuroRestore platform and its leading drug candidate ACD856 show good properties for the further clinical development in Alzheimer’s disease with potential for both memory-enhancing and disease-modifying effects”, said Martin Jönsson, CEO of AlzeCure Pharma.

The presentations and abstracts are available on AlzeCure’s website: